Back to top

crispr: Archive

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected

CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.

JNJNegative Net Change VRTXPositive Net Change CRSPNegative Net Change CRBUPositive Net Change

Zacks Equity Research

Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View

Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.

NVSNegative Net Change JNJNegative Net Change VRTXPositive Net Change CRSPNegative Net Change